Skip to content
Multiple Sclerosis News Today logo Newsletter
Newsletter
  • About MS
    Multiple sclerosis overview
    • Types of MS
    • Causes and risk factors
    • Symptoms
    • Diagnosis
    • Living with MS
    Treatments options for MS
    • Approved treatments
    • Experimental treatments
    Clinical Trials
    • What are clinical trials?
    • Types of clinical trials
    • How do clinical trials work?
    • Traditional vs. remote vs. hybrid clinical trials
    • FAQs about clinical trials
  • Featured Topics
    Newly diagnosed guide
    • Continuing MS treatment
    • MS and employment
    • Next steps after an MS diagnosis
    • MS caregivers guide
    • MS healthcare team
    • Perspectives on MS diagnosis
    • MS treatment explainer
    • Questions to ask your doctor
    • Guidelines for MS diagnosis
    • Physical activity and quality of life
    • View all
    MS pathways
    • MS and sleep
    • Videos: Worth the talk
    • Managing RRMS
    • Changing MS therapy
    • Mental health and MS
    • MS spasticity stretches
    • MS apps and tools
    • Energy levels and MS
    • MS and eating
    Living strong
    • MS and chronic pain
    • Stress and MS
    • MS and exercise
    • MS safe home tips
    • MS in women
    • Talking to your doctor
    • Recognizing MS symptoms
    • MS and restless leg syndrome
    Resources
    • MS hug
    • MS and heat
    • Cannabis and MS
    • Lesions and MS
    • Myelin's role in MS
    • Epstein-Barr virus and MS
    • Stem cell therapy for MS
    • MS prognosis and life expectancy
    • MS and mental health
    Expert voices
    • Exercise
    • Pain management
    • Cannabis use
    • Diet and nutrition
    • Financial planning
    • Managing fatigue
    • Sleeping well
    • More
  • News
  • Columns
    Authentically Human – Desiree Lama
    Balancing Grit and Grace – Ahna Crum
    Chairborne — Ben Hofmeister
    Delicate Balance – Leigh Anne Nelson
    Rhythms and Routines – Susan Payrovi, MD
    Archived Columns
    • A Life in Letters — Jamie Hughes
    • DISabled to ENabled — Jessie Ace
    • Dive to Fight MS – Mike Parker
    • Fall Down, Get Up Again — John Connor
    • Goldilochs — Stephen De Marzo
    • Patiently Awakened — Teresa Wright-Johnson
    • The MS Wire — Ed Tobias
    • Silver Linings — Jennifer Powell
    In memoriam
    • Through the Looking Glass — Beth Shorthouse-Ullah
  • Forums
  • Video & Podcasts
    Get Tough on Multiple Sclerosis Video Series
    Get Tough on Multiple Sclerosis Podcast
    The Multiple Sclerosis Podcast
  • Advocacy partners
  • What can we help you find today?

December 17, 2020 News by Joana Carvalho, PhD

Progressive MS Patients Urged to Enroll in Phase 3 Trials of Tolebrutinib

Investigators are looking for people with progressive forms of multiple sclerosis (MS) to participate in two Phase 3 clinical trials assessing the safety and effectiveness of tolebrutinib (SAR442168), an oral BTK inhibitor that is being investigated as a potential treatment, the National Multiple Sclerosis Society announced…

December 14, 2020 News by Diana Campelo Delgado

Sanofi Enrolling for 2 GEMINI Trials Testing Tolebrutinib vs. Aubagio for Relapsing MS

Two global Phase 3 clinical trials, both comparing Sanofi Genzyme’s investigational tolebrutinib with its approved therapy Aubagio, are enrolling a total of 1,800 people with relapsing multiple sclerosis (MS), the company said. All patients in both studies — dubbed GEMINI 1 and GEMINI 2 — will…

September 11, 2020 News by Joana Carvalho, PhD

#MSVirtual2020 – Tolebrutinib Prevents Myelin Loss in Mouse Model of MS-like Demyelination

Tolebrutinib (SAR442168), an investigational oral BTK inhibitor to treat relapsing forms of multiple sclerosis (MS), was seen to prevent the loss of myelin when given to a mouse model of demyelination in a preclinical study. The investigative therapy achieves this by preventing…

August 19, 2020 News by Joana Carvalho, PhD

Sanofi to Acquire Principia Biopharma in $3.6 Billion Transaction

In a $3.68 billion transaction, Sanofi is preparing to acquire Principia Biopharma, a biopharmaceutical company focused on the development of therapies for disorders caused by dysregulation of the immune system, including multiple sclerosis (MS). The decision was unanimously approved by the board of directors of…

June 25, 2020 News by Joana Carvalho, PhD

1st Relapsing MS Patient Enrolls in Phase 3 Trial of Oral SAR442168

A first person has enrolled in Sanofi’s Phase 3 trial evaluating SAR442168, an oral BTK inhibitor intended to treat relapsing forms of multiple sclerosis (MS), Sanofi’s partner, Principia Biopharma, announced. “We are delighted that Sanofi has initiated … [this] trial in patients with relapsing MS,” Roy Hardiman, chief…

May 4, 2020 Columns by Ed Tobias

MS News that Caught My Eye Last Week: Diagnosis by Antibody, Ocrevus After 6 Years, Telemedicine, New DMT Pill

New Nanosensor May Help to Diagnose MS at Early Stages My neurologist likes to say that “brain is time.” The sooner MS is treated the more time you can buy before the brain begins to deteriorate and MS symptoms appear. Being able to diagnose MS sooner means earlier treatment.

April 24, 2020 News by Marisa Wexler, MS

Sanofi’s BTK Inhibitor Seen to Effectively Reduce Brain Lesions in Phase 2 Trial

The investigational, oral BTK inhibitor SAR442168 can limit the number of new inflammatory brain lesions in people with relapsing forms of multiple sclerosis (MS), results from a Phase 2b clinical trial show. “The results of this study give hope that SAR442168 may become an important…

April 20, 2020 News by Marisa Wexler, MS

Sanofi to Detail Trial Results of Oral Relapsing MS Therapy Online on Thursday

Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety and efficacy of its investigational, oral BTK inhibitor SAR442168 in people with multiple sclerosis (MS). The virtual session, owing to the cancellation of the American Academy…

February 7, 2020 News by Marisa Wexler, MS

Mayzent Approved in Europe as First Oral Treatment for Active Secondary Progressive MS

The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant reduction in the number of new lesions visible on a brain imaging scan — in a Phase 2 trial in people with multiple sclerosis (MS), study results show. SAR442168,…

May 24, 2019 News by Vijaya Iyer, PhD

First Patient Dosed in Phase 2B Trial Testing SAR442168 Therapeutic Candidate for RRMS

The first patient has been dosed in a Phase 2B clinical trial evaluating the safety, efficacy, and tolerability of SAR442168 in people with relapsing multiple sclerosis (MS). SAR442168, formerly known as PRN2246, is being developed by Principia Biopharma, in collaboration with Sanofi Genzyme, for MS and other central nervous…

Recent Posts

  • Estrogen, aging, and MS: Notes from the front lines of midlife
  • T-cells help protect against risk of COVID-19 infection in MS: Study
  • Varying impact on risk of stroke found for DMT use in MS in study


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.